From the Montreal Heart Institute, Université de Montréal, Montreal (T.F.K., M.-A.L., C.V., R.C., D.R., M.T., M.D., B.T., P.G.G., L.R., K.D., B.M., R.T., J.C.-T., L.M., P.K.); Instituto Nacional de Cardiologia, Ignacio Chavez, Mexico City (S.N.); the Dominican Institute of Cardiology, Santo Domingo, Dominican Republic (F.V.B.); Clínicas Médicas las Américas, Guatemala City, Guatemala (F.S.O.); and Cardiología Hospital General del Sur, Choluteca (N.E.L.O.), and Instituto Nacional Cardiopulmonar (G.S.M.) and Medicina Interna-Programación de Marcapaso Definitivo, Instituto Nacional Cardiopulmonar, Tegucigalpa (C.A.C.) - all in Honduras.
N Engl J Med. 2020 May 7;382(19):1823-1831. doi: 10.1056/NEJMoa1813876.
Access to pacemakers and defibrillators is problematic in places with limited resources. Resterilization and reuse of implantable cardiac devices obtained post mortem from patients in wealthier nations have been undertaken, but uncertainty around the risk of infection is a concern.
A multinational program was initiated in 1983 to provide tested and resterilized pacemakers and defibrillators to underserved nations; a prospective registry was established in 2003. Patients who received reused devices in this program were matched in a 1:3 ratio with control patients who received new devices implanted in Canada. The primary outcome was infection or device-related death, with mortality from other causes modeled as a competing risk.
Resterilized devices were implanted in 1051 patients (mean [±SD] age, 63.2±18.5 years; 43.6% women) in Mexico (36.0%), the Dominican Republic (28.1%), Guatemala (26.6%), and Honduras (9.3%). Overall, 85% received pacemakers and 15% received defibrillators, with one (55.5%), two (38.8%), or three (5.7%) leads. Baseline characteristics did not differ between these patients and the 3153 matched control patients. At 2 years of follow-up, infections had occurred in 21 patients (2.0%) with reused devices and in 38 (1.2%) with new devices (hazard ratio, 1.66; 95% confidence interval, 0.97 to 2.83; P = 0.06); there were no device-related deaths. The most common implicated pathogens were and .
Among patients in underserved countries who received a resterilized and reused pacemaker or defibrillator, the incidence of infection or device-related death at 2 years was 2.0%, an incidence that did not differ significantly from that seen among matched control patients with new devices in Canada.
在资源有限的地方,起搏器和除颤器的获取存在问题。已经对从富裕国家的死亡患者身上获取的可植入心脏设备进行了再消毒和再利用,但感染风险的不确定性仍然令人担忧。
1983 年启动了一个跨国计划,为服务不足的国家提供经过测试和再消毒的起搏器和除颤器;2003 年建立了一个前瞻性登记处。该计划中使用再利用设备的患者与在加拿大植入新设备的对照组患者以 1:3 的比例进行匹配。主要结局是感染或与器械相关的死亡,其他原因导致的死亡率被建模为竞争风险。
在墨西哥(36.0%)、多米尼加共和国(28.1%)、危地马拉(26.6%)和洪都拉斯(9.3%),对 1051 例(平均[±SD]年龄,63.2±18.5 岁;43.6%为女性)患者进行了再消毒设备的植入。总体而言,85%的患者接受了起搏器,15%的患者接受了除颤器,其中 1 个(55.5%)、2 个(38.8%)或 3 个(5.7%)导联。这些患者与 3153 例匹配的对照组患者的基线特征没有差异。在 2 年的随访期间,使用再利用设备的患者中有 21 例(2.0%)发生感染,使用新设备的患者中有 38 例(1.2%)发生感染(风险比,1.66;95%置信区间,0.97 至 2.83;P=0.06);没有与器械相关的死亡。最常见的感染病原体为 和 。
在资源匮乏国家接受再消毒和再利用的起搏器或除颤器的患者中,2 年内感染或与器械相关的死亡发生率为 2.0%,与加拿大接受新器械的匹配对照组患者的发生率无显著差异。